TBL-12 is a 100% natural product extracted from the sea cucumber, sea sponge, sea urchin, and selected sea grasses. The extract is a unique concentrate of protein enzyme, omega 3 fats, essential vitamins, minerals, trace minerals, and 18 amino acids. It is a clinically tested natural immune modulator which exhibits potent anti-inflammatory properties.
First available in 1981 as a dietary supplement, TBL-12 is essentially a food, similar to meat, fish or vegetables. It is safe to use with conventional medical treatments, and has been used as a complementary and alternative cancer treatment without any reported toxicity. It has been shown to possess anti-tumor properties, including direct tumor toxicity and anti-angiogenesis. It has also been effective in inducing cell growth inhibition.
TBL-12 is used as a complementary and alternative therapy in the treatment of cancer, and patients who have an auto immune disease. It is a natural immune modulator, and a powerful anti-inflammatory which can modulate the symptoms of cancer and many other diseases. One of the most encouraging research findings is that sea cucumber extract can block the growth of several different types of cancer cells, including pancreatic cancer.
Anecdotal evidence provided by patients who have used TBL-12 as an alternative cancer treatment, or in conjunction with conventional treatments, indicate that it is effective in moderating symptoms, reducing side effects of conventional therapies, and has allowed many to regain a quality of life they had lost through their illness.
These reports have come from patients suffering many different cancers and immune diseases including late stage multiple myeloma, leukaemia, melanoma, breast cancer, prostate cancer, and mesothelioma, and auto immune diseases such as psoriasis, chronic fatigue syndrome, lupus, multiple sclerosis, IBS and many more.
TBL-12 is currently involved in two clinical trials assessing the value in using the product to treat Multiple Myeloma. One of these is a phase ii study. Currently, trials with TBL-12 are being conducted at the NYU Cancer Institute, USA.
“A Phase II Trial of TBL 12 Sea Cucumber Extract in Patients With untreated Asymptomatic Myeloma” is being conducted by the noted myeloma expert, Sundar Jagannath, MD, with colleagues Amitabha Mazumder, MD and Ajai Chari, MD. At the New York University School of Medicine, Clinical Cancer Center
Conclusions of this phase 2 study so far:
In this pilot study of high risk ASxMM patients, TBL-12 was well tolerated and 11 patients (65%) remain on treatment. The expected rate of progression for this population from diagnosis is 52%at 2 years, however, the median time to progression has not been yet reached in this study. The decrease in the rate of rise in the m-spike in a high risk patient concomitant with the initiation of study treatment is suggestive of a biologic effect of TBL-12 in MM and warrants further study of TBL-12 in a larger cohort of patients. More clinical trials to target other cancer types and immune disorders are being planned.
PROS AND CONS
What is good and what is bad about TBL-12
Please take a moment to RATE THIS SITE. If there is something more you think should be included, use the Contact Information Page and let us know.